Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748721 · ClinicalTrials.gov registry record · Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Morphotek.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01748721 is a Phase 1 study that has completed, run by Morphotek. The registered enrollment target is 27 participants.
The verdict
NCT01748721, a Phase 1 study, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- BIOLOGICAL anti-endosialin/TEM1 monoclonal antibody MORAb-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01748721
The ClinicalTrials.gov registry entry for NCT01748721 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01748721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01748721 about?
NCT01748721 is a clinical study titled "MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma". This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others fi...
What is the current status of trial NCT01748721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2013-11. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01748721?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), anti-endosialin/TEM1 monoclonal antibody MORAb-004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01748721?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.